Flotufolastat F-18: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Flotufolastat F-18. Educational only — not medical advice.

Labeled uses

POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Source: FDA labeling via NIH DailyMed (set 907ac4a4…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.